It explains the State Farm agent experience with a flow chart of agent progression through the program, and includes agent testimonials. The brochure does not include any test questions, but the website may be used to find local agents who may be willing to share some tips.
The secondary objectives are safety profile and the response rate. Lapatinib, an oral inhibitor of EGFR and HER2, have been shown to be an effective treatment in HER2/neu overexpressing metastatic breast cancer patient who refractory herceptin, taxane, and anthracycline treatment.
The approval was based on a randomized, controlled trial of sunitinib, 37.5 mg/d, (n=86) orally versus placebo (n=85) in patients with unresectable, locally advanced, or metastatic well-differentiated pNET.dverse events resulted in permanent discontinuation in 22% and 17% of patients in the sunitinib and placebo arms, respectively. Dose delays and/or reductions were necessary in 61% of sunitinib and 23% of placebo patients. The recommended dose and schedule for sunitinib is 37.5 mg orally daily.